Eyetech Pharmaceuticals Inc. could gain about $750 million in a deal with Pfizer Inc. centered on development and commercialization of Macugen, Eyetech's lead drug candidate for age-related macular degeneration and diabetic macular edema. (BioWorld Today)

Eyetech Pharmaceuticals Inc. could gain about $750 million in a deal with Pfizer Inc. centered on development and commercialization of Macugen, Eyetech's lead drug candidate for age-related macular degeneration and diabetic macular edema. (BioWorld Today)

By dropping children younger than 5 from its label, MedImmune Inc. was able to convince an FDA panel of experts that the intranasal influenza vaccine FluMist is safe and efficacious in people ages 5 to 49. (BioWorld Today

By dropping children younger than 5 from its label, MedImmune Inc. was able to convince an FDA panel of experts that the intranasal influenza vaccine FluMist is safe and efficacious in people ages 5 to 49. (BioWorld Today

While The Street is leaning toward a favorable vote for MedImmune Inc.'s FluMist as an intranasal influenza vaccine, it's not so clear whether Seattle-based Corixa Inc. will get the nod for its cancer drug, Bexxar. (BioWord Today)